STERIS agreed to acquire Xodus Medical for $2.1 billion in a debt-funded deal closing by year-end. The Dublin-based provider of hospital and pharmaceutical products is targeting Xodus's extraordinary 55% operating margin, nearly triple STERIS's own 19%. STERIS is paying an $8.6 revenue multiple and a $15.6 operating profit multiple, betting that Xodus's recurring revenue and growth can be integrated successfully.
The $2.1 billion debt load, nearly double STERIS's annual free cash flow, exposes the company to margin reversion risks if Xodus's profit rate or growth falters post-acquisition. Tax benefits worth $300 million in net present value reduce the effective price to $1.8 billion, with a further $150 million contingent on Xodus hitting performance targets in 2028. Viewed proportionally, Xodus represents roughly 4% of STERIS's $6 billion in trailing revenue, making this a disciplined roll-up of high-margin consumables rather than a transformation.
The deal is mechanically accretive because Xodus's operating yield on the net outlay comfortably exceeds STERIS's after-tax cost of debt, and folding a 55%-margin business into a 19%-margin company drags the blended number upward on paper regardless of operational improvements.
Source: Wall Street Journal Markets · Summarized by HeadlinesBriefing